Dear E-drug readers,
I published today this comment in The Lancet on the recent decision by the Indian Patent Office to grant a patent for the hepatitis-C drug sofosbuvir and the options countries have through compulsory licensing in accessing generic supply.
I hope this is useful and feel free to circulate widely.
http://www.thelancet.com/pb/assets/raw/Lancet/pdfs/S0140673616306560.pdf
Kind regards,
Ellen 't Hoen, LLM | Medicines Law & Policy
phone: +31 (0) 6 375 30 700
e-mail: ellenthoen@medicineslawandpolicy.net twitter:@ellenthoen
skype: efmthoen